-
A Brazilian company has begun test production of the active ingredient for Russia's Sputnik V vaccine for COVID-19 and plans to reach full manufacturing in April, as reported Financial Post on Thursday.
-
"This week we started making a pilot lot of the active ingredient for learning purposes, not for use," said Miguel Giudicissi, chief science officer at União Quimica.
-
Giudicissi said União Quimica's contract with the Russian Direct Investment Fund (RDIF), which is marketing the vaccine, provides for a 100% transfer of technology, adding that "this will give Brazil autonomy in COVID-19 vaccine supplies."
-
The partners will provide additional Phase III clinical trial data involving 22,000 participants in Russia from the 44,000-subject programme that should convince Anvisa that Sputnik V is safe and has an efficacy of 90%, Giudicissi added.
To read more NewsPoints articles, click here.
